BioCentury
ARTICLE | Product Development

Akero to advance NASH therapy in patients with compensated cirrhosis following Phase IIa readout

March 24, 2021 12:34 AM UTC

While Akero’s NASH therapy did not lead to the same levels of efficacy in patients with compensated cirrhosis as it did in less severe patients, the company views the data as sufficient to move into Phase IIb testing next half. 

Akero Therapeutics Inc. (NASDAQ:AKRO), a front-runner among NASH companies, announced on Monday results from an expanded cohort of the 16-week Phase IIa BALANCED trial evaluating a once-weekly 50 mg dose of efruxifermin in NASH patients with stage 4 fibrosis and Child-Pugh Class A...

BCIQ Company Profiles

Akero Therapeutics Inc.